Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose University of Galway as their University of choice. Find out what life at University of Galway is all about here.
About University of Galway
About University of Galway
Since 1845, University of Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
University of Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a range of key areas of expertise.
- Research & Innovation
Business & Industry
Guiding Breakthrough Research at University of Galway
We explore and facilitate commercial opportunities for the research community at University of Galway, as well as facilitating industry partnership.
- Alumni & Friends
At University of Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
March 2016 NUI Galway Scientists Discover Black Fever Tropical Disease Beats Drugs Treatment
NUI Galway Scientists Discover Black Fever Tropical Disease Beats Drugs Treatment
By adding just two DNA bases to its genome NUI Galway scientists have discovered that Black Fever, the second most deadly parasitic disease, can become resistant to drug treatment
Scientists from NUI Galway and the Wellcome Trust Sanger Institute in the UK have shown how the parasite responsible for the neglected tropical disease Black Fever (visceral leishmaniasis) can become resistant to drug treatment, published today in the life sciences and biomedicine journal eLife.
Studying the whole genomes (every single letter of the organism’s DNA code) of more than 200 samples of Leishmania donovani parasites revealed that the addition of just two bases of DNA to a gene known as LdAQP1 stops the parasite from absorbing antimonial drugs.
While antimonials (a group of compounds used for the treatment of leishmaniasis) are no longer the first-line treatment for the disease, the discovery does show that whole-genome sequencing of Leishmania donovani parasites could be used to study and track the emergence of resistance to frontline drugs – alerting health workers to potential outbreaks of resistance.
Black Fever is the second most deadly parasitic disease after malaria, affecting nearly 300,000 people every year and killing up to 50,000. The parasite is mainly found in the Indian subcontinent, where up to 80 per cent of the disease occurs. To best understand how the parasite evolves and track the spread of drug resistance, researchers need a way to survey and monitor the parasite’s population structure. Unfortunately standard techniques to do this have proved fruitless because the strains of L. donovani parasite are so genetically similar.
Dr Tim Downing, one of the paper’s first authors from NUI Galway and the Sanger Institute said: “We discovered that many of the parasites that were resistant to antimonial drug treatment had just two additional DNA bases in the gene LdAQP1, which produces an aquaglyceroporin protein. This insertion produces a scrambled version of this protein that can no longer move small molecules – including antimonials – across its cell membrane. These strains of L. donovani are likely to be resistant because they cannot take in the drugs.”
Dr James Cotton, senior author of the study from the Sanger Institute said: “If you want to control visceral leishmaniasis, you need to understand what is going on at the geographic epicentre of the disease, and you need to be able to see changes at the level of individual DNA bases in the parasites’ genomes. Until now studies have been limited to looking at small regions of the parasite’s DNA or at what happens in the laboratory. To truly understand what is happening in the real world, we analysed the whole genomes of more than 200 samples from parasites captured in India, Nepal and Bangladesh over almost a decade.”
Exploring the genetic landscape of L. donovani at such depth and breadth yielded new insights into the parasites’ ability to develop drug resistance, and its evolutionary history. In particular, the researchers found that the insertion of just two extra bases of DNA at this single LdAQP1 (aquaglyceroporin) gene in a genome with over 8,000 genes helped the parasite to overcome antimonial drugs.
Black Fever – “kala azar” in Hindi – is the second largest life-threatening parasitic disease after malaria. Spread through the bites of sandflies, the parasites enter the internal organs such as the liver, spleen and bone marrow, making them inflamed and swollen. The infection produces fever, weight loss, fatigue and anaemia and is fatal if left untreated.
Professor Jean-Claude Dujardin of the Institute of Tropical Medicine Antwerp and the University of Antwerp, senior author of the study and leader of the consortium that ran the study said: “This study perfectly illustrates the relevance of collaboration between large sequencing centres like the Sanger Institute and clinicians and scientists involved in the battle against the most neglected diseases. Thanks to the acquired knowledge, it will be our turn now to beat Black Fever 2-0 by providing local health authorities with performance monitoring tools, and guiding research and development for new and more efficient anti-parasitic drugs.”
Analysis of the genomes by the researchers revealed that the parasites responsible for the current epidemic first appeared in the Indian subcontinent in the 19th Century, matching the first historical records of Black Fever epidemics.
In addition, the current genetic diversity of the parasite traces back to the 1960s, around the time that the widespread use of DDT to eradicate malaria in India came to an end.
To read the full paper in eLife visit: http://dx.doi.org/10.7554/eLife.12613